Infinity Pharmaceuticals (INFI) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INFI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INFI, but not buy additional shares or sell existing shares.
View INFI analyst ratings or view top-rated stocks.

2 analysts have issued 1-year price targets for Infinity Pharmaceuticals' stock. Their INFI share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 7,042.9% from the stock's current price.
View analysts price targets for INFI or view top-rated stocks among Wall Street analysts.

Infinity Pharmaceuticals' stock was trading at $0.5550 at the beginning of the year. Since then, INFI stock has decreased by 96.2% and is now trading at $0.0210.
View the best growth stocks for 2023 here.

Infinity Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,210,000 shares, an increase of 12.2% from the August 15th total of 1,970,000 shares. Based on an average trading volume of 3,370,000 shares, the days-to-cover ratio is currently 0.7 days.
View Infinity Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our INFI earnings forecast.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) announced its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($0.11) EPS for the quarter. The biotechnology company earned $0.58 million during the quarter.

10 employees have rated Infinity Pharmaceuticals Chief Executive Officer Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among the company's employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Carlson Capital L P (1.45%), Renaissance Technologies LLC (0.40%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Adelene Q Perkins and Bvf Partners L P/Il.
View institutional ownership trends.

Shares of INFI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFI stock can currently be purchased for approximately $0.02.

Infinity Pharmaceuticals (NASDAQ:INFI) has a market capitalization of $1.91 million and generates $2.57 million in revenue each year. The biotechnology company earns $-44,370,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The official website for the company is www.infi.com. The biotechnology company can be reached via phone at (617) 453-1000, via email at irpr_info@infi.com, or via fax at 617-453-1001.